Stoke Therapeutics CEO to Present at Guggenheim Biotech Summit 2026 — Stoke Therapeutics, Inc.

Event summary

Stoke Therapeutics CEO Ian F. Smith to present at Guggenheim Biotech Summit on February 11, 2026.
Presentation scheduled for 2:30 p.m. ET, with live webcast and replay available.
Stoke's lead investigational medicine, zorevunersen, is in Phase 3 trials for Dravet syndrome.
Zorevunersen has received orphan drug, rare pediatric disease, and Breakthrough Therapy designations from FDA and EMA.
Stoke has a strategic collaboration with Biogen for global commercialization of zorevunersen.

The big picture

Stoke Therapeutics' presentation at the Guggenheim Biotech Summit comes as the company advances its lead candidate, zorevunersen, through critical Phase 3 trials. The strategic collaboration with Biogen positions Stoke for potential global expansion, while regulatory designations highlight the therapeutic promise of its RNA medicine approach. The biotech sector continues to focus on disease-modifying treatments, particularly for rare genetic disorders like Dravet syndrome.

What we're watching

Clinical Progress: The pace at which zorevunersen advances through Phase 3 trials will determine its market potential.
Regulatory Pathway: Whether the Breakthrough Therapy designation will accelerate FDA approval for zorevunersen.
Commercial Strategy: How Stoke and Biogen will navigate global commercialization under their strategic collaboration.